The impact of sodium‐glucose co‐transporter‐2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation

SGLT2i use was associated with a 71% lower risk of incident dementia in diabetic patients with atrial fibrillation over up to 5 years of follow-up.

• SGLT2i was linked to a significantly reduced risk of vascular dementia (HR: 0.44).
• Use of SGLT2i was associated with lower rates of AF-related hospitalisation (HR: 0.72).
• Patients on SGLT2i had a reduced risk of stroke (HR: 0.75).
• SGLT2i was related to a lower risk of all-cause death (HR: 0.33).
• The protective effects of SGLT2i were consistent regardless of concurrent use of non-vitamin K antagonist oral anticoagulants or DPP4i.

AI simplified